医保改革后，个人账户划入减少了？药店也都快撑不住了

Core Insights - The retail pharmacy industry in China, once perceived as highly profitable, is facing significant challenges as the number of closures increases rapidly, with 8,792 pharmacies shutting down in Q2 2024 alone [1][3] - The reform of the medical insurance personal account system, initiated in 2021, has led to a substantial reduction in available funds for consumers, negatively impacting pharmacy revenues [3][5] - Consumer behavior is shifting towards more price-sensitive purchasing, with many opting to visit hospitals for treatments instead of using their limited insurance funds at pharmacies [5][8] Summary by Sections Industry Overview - As of Q2 2023, there are 701,000 pharmacies in China, with an average of 2,000 people served per pharmacy, indicating potential market growth compared to developed countries [1] - The number of pharmacy closures has surged, with 6,778 closures in Q1 2024 and 8,792 in Q2 2024, highlighting a severe industry crisis [1] Impact of Medical Insurance Reform - The medical insurance reform aims to transition funding from a per capita distribution to a disease-based payment system, which has resulted in a decrease in personal account funds [3] - In 2023, the total income of medical insurance personal accounts dropped from 763.3 billion yuan in 2022 to 635.1 billion yuan, representing a significant decline [3] Consumer Behavior Changes - The reduction in personal account funds has led to a 9% year-on-year decrease in spending from these accounts on medications in 2023 [5] - Consumers are becoming more budget-conscious, often choosing to compare prices and select cheaper medications, reflecting a shift in purchasing behavior due to financial constraints [5][8] Market Saturation and Competition - The market is experiencing over-saturation, with many areas having multiple pharmacies within close proximity, leading to intensified competition and reduced market share for individual pharmacies [8] - The combination of insurance reform and market saturation is creating unprecedented survival challenges for retail pharmacies, diminishing their previous reputation as a lucrative industry [8]